ASA Biopharmaceutical Report

ASA Biopharmaceutical Report

Share this post

ASA Biopharmaceutical Report
ASA Biopharmaceutical Report
Summary of ASA BIOP Section’s Virtual Discussion with Regulators on Trial Considerations in Indolent Cancers with Overall Survival as a Safety Endpoint

Summary of ASA BIOP Section’s Virtual…

ASA Biopharmaceutical Report
Apr 15

Share this post

ASA Biopharmaceutical Report
ASA Biopharmaceutical Report
Summary of ASA BIOP Section’s Virtual Discussion with Regulators on Trial Considerations in Indolent Cancers with Overall Survival as a Safety Endpoint

Rajeshwari Sridhara (FDA), Olga Marchenko (Bayer), Qi Jiang (Pfizer), Elizabeth Barksdale (LUNGevity Foundation), Yiyi Chen (Pfizer), Marc Theoret (FDA)

Read →
Comments
User's avatar
© 2025 ASA Biopharmaceutical Report
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share